论文部分内容阅读
目的：比较诺维本持续静脉输注与常规用法治疗晚期非小细胞肺癌的疗效和毒性。方法：统计分析持续静脉输注和常规用法组治疗的49例晚期非小细胞肺癌病例的临床资料。结果：持续输注组有效率为48％，常规用法组有效率为41．7％，前者略高于后者，两者比较无显著差异（P ＞0．05，但达到有效所用的时间前者平均56天，后者为89天，两者比较有显著差异（P＜ 0．05。毒副反应主要为骨髓抑制和局部静脉炎。结论：持续静脉输注诺维本是治疗晚期非小细胞肺癌较为有效而安全的新方法。
OBJECTIVE: To compare the efficacy and toxicity of Navelbine continuous intravenous infusion and conventional use in the treatment of advanced non-small cell lung cancer. METHODS: The clinical data of 49 cases of advanced non-small cell lung cancer treated with continuous intravenous infusion and conventional treatment group were statistically analyzed. Results: The effective rate was 48% in the continuous infusion group and 41.7% in the conventional use group. The former was slightly higher than the latter, and there was no significant difference between the two groups (P>0.05 , but the effective time was used. The former had an average of 56 days and the latter was 89 days. There was a significant difference between the two groups (P<0.05). The toxicity was mainly myelosuppression and local phlebitis. Conclusion: Continuous intravenous infusion of Navelbine is a treatment for advanced non- Small cell lung cancer is a more effective and safe new method.